Odense Universitetshospital

The trials here

What the 26 trials at this site are about, from their registry records.

Conditions

• Bladder cancer3 trials
• Childhood cancers2 trials
• Colorectal cancer2 trials
• COPD2 trials
• HIV2 trials
• Lung cancer2 trials
• Multiple sclerosis2 trials
• Obesity2 trials
• Pancreatic cancer2 trials
• Ulcerative colitis2 trials
• Acute lymphoblastic leukaemia1 trial
• Acute myeloid leukaemia1 trial
• and 22 more

Phase

• Phase 39 trials
• Phase 26 trials
• Phase 42 trials
• Phase 2/31 trial

Status

• Active, not recruiting10 trials
• Recruiting10 trials
• Completed4 trials
• Enrolling by invitation1 trial
• Terminated1 trial

Lead sponsor

• Copenhagen University Hospital, Rigshospitalet4 trials
• Eli Lilly and Company3 trials
• Acacia Pharma Ltd1 trial
• Biogen1 trial
• Christoffer Johansen1 trial
• and 16 more

Running trials

• Recruiting

  Implementing the 6th Generation Cardiac Troponin T

  NCT07936630· Rasmus Bo Hasselbalch· Source

  Contact: Rasmus Hasselbalch, Md, PhD

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Eli Lilly and Company· Source

  Contact: Mark Ainsworth (principal investigator)

• Active, not recruiting

  A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

  NCT07015983· Phase 2· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

  Contact: Jens Kjeldsen (principal investigator)

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

  Contact: Jens Kjeldsen (principal investigator)

• Recruiting

  Thrombolysis in Factor Xa-inhibitors Trial

  NCT06878066· Phase 3· Guri Hagberg· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps

  NCT05942222· Phase 4· Copenhagen University Hospital, Rigshospitalet· Source

• Recruiting

  Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer

  NCT05788744· Copenhagen University Hospital at Herlev· Source

  Contact: Michael B Mortensen

• Active, not recruiting

  The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events

  NCT05421286· Copenhagen University Hospital, Rigshospitalet· Source

• Recruiting

  Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)

  NCT05444348· Christoffer Johansen· Source

  Contact: Cæcilie Borregaard Myrhøj

• Active, not recruiting

  Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer

  NCT04742075· Phase 2· Nordic Society of Gynaecological Oncology - Clinical Trials Unit· Source

• Active, not recruiting

  A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

  NCT05070858· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures

  NCT04851717· Phase 2/3· Acacia Pharma Ltd· Source

• Recruiting

  Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors

  NCT04916132· Herlev Hospital· Source

  Contact: Karoline Schousboe

• Active, not recruiting

  Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

  NCT04688788· Phase 3· Copenhagen University Hospital, Rigshospitalet· Source

• Active, not recruiting

  Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy

  NCT04138628· Phase 2· Jørgen Bjerggaard Jensen· Source

• Recruiting

  The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

  NCT04075305· UMC Utrecht· Source

  Contact: Tine Schytte

• Active, not recruiting

  Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer

  NCT03299478· University Hospital of North Norway· Source

• Active, not recruiting

  Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial

  NCT01558921· Phase 3· University Medical Center Groningen· Source

• Enrolling by invitation

  EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV

  NCT02699736· Copenhagen University Hospital, Rigshospitalet· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer2 recruiting
• Obesity2 recruiting
• Pancreatic cancer2 recruiting
• Ulcerative colitis2 recruiting
• Acute myeloid leukaemia1 recruiting
• Atrial fibrillation1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Colorectal cancer1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Hepatitis B1 recruiting
• Hepatitis C1 recruiting
• HIV1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Prostate cancer1 recruiting
• Stroke1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05037929· Phase 2· Genentech, Inc.· Source

• Completed

  CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  NCT04136171· Phase 3· Ionis Pharmaceuticals, Inc.· Source

• Completed

  Copd Exacerbation and Pulmonary Hypertension Trial

  NCT04538976· Phase 4· Chronic Obstructive Pulmonary Disease Trial Network, Denmark· Source

• Completed

  Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

  NCT02283853· Phase 3· Biogen· Source